EYENOVIA INC. - COMMO

Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities

08 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

03 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

18 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

13 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery

05 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility

13 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada

16 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update

13 Nov 2023 16:05:01 By Nasdaq GlobeNewswire

Eyenovia to Report Third Quarter 2023 Results on Monday, November 13

06 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®

09 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference

21 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference

07 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces $12 Million Registered Direct Offering

24 Aug 2023 18:47:29 By Nasdaq GlobeNewswire

Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals

16 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update

10 Aug 2023 16:05:01 By Nasdaq GlobeNewswire

Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

09 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10

07 Aug 2023 08:00:01 By Nasdaq GlobeNewswire